ABBV vs MS: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-16.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Morgan Stanley · Financial Services
$206.27
+15.9% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MS has more upside to fair value
(+15.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MS |
| Current Price |
$261.70 |
$206.27 |
| Fair Value Estimate |
$259.04 |
$239.00 |
| Upside to Fair Value |
-1.0%
|
+15.9%
|
| Market Cap |
$462.4B |
$325.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
23.5x
|
| Price / Sales |
7.2x
|
2.6x
|
| Price / FCF |
23.6x
|
—
|
| Revenue Growth YoY |
+10.2%
|
+22.4%
|
| Gross Margin |
71.5%
|
59.7%
|
| Operating Margin |
29.3%
|
20.7%
|
| Return on Equity |
-136.5%
|
18.1%
|
| Dividend Yield |
2.61% |
2.01% |
| FCF Yield |
4.25%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Morgan Stanley is a diversified capital-markets and wealth-management franchise spanning institutional securities, advisor-led and self-directed wealth, workplace services, and investment management. Business quality is solid but inherently cyclical: it combines $8.084 trillion of wealth client assets and $2.004 trillion of investment-management AUM/AUS with a strengthening 15.5% institutional pe…
Accumulation Zones
| Metric |
ABBV |
MS |
| Zone Low |
$194.28 |
$179.25 |
| Zone High |
$220.18 |
$203.15 |
| In Buy Zone? |
No
|
No
|